Quick Answer
enGene Therapeutics Inc. reported Stockholders Equity of $167.71 million for fiscal year 2025.
enGene Therapeutics Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $167.71M | -38.5% |
| 2024 | $272.61M | +276.1% |
| 2023 | $72.49M | +194.6% |
| 2022 | -$76.61M | -43.4% |
| 2021 | -$53.44M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | $281.55M | +12.6% | +67.9% |
| October 31, 2025 | $167.71M | -38.5% | -16.4% |
| July 31, 2025 | $200.67M | -12.9% | -11.7% |
| April 30, 2025 | $227.29M | -6.5% | -9.1% |
| January 31, 2025 | $249.95M | +300.7% | -8.3% |
| October 31, 2024 | $272.61M | +276.1% | +18.4% |
| July 31, 2024 | $230.33M | +345.2% | -5.2% |
| April 30, 2024 | $242.97M | +372.3% | +289.5% |
- enGene Therapeutics Inc. showed a decrease of -38.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2021–2025 period, enGene Therapeutics Inc.’s stockholders equity has grown by 413.8% (from -$53.44 million to $167.71 million).
- The most recent figure is from enGene Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 22, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: